Generic drugs get a legal boost from Supreme Court ruling, law firm analysis finds

Brand-name drugmakers face a steeper climb when trying to sue generic competitors over patented uses carved out of a "skinny label," according to a new analysis from law firm Ballard Spahr, which flags the practical fallout for pharmaceutical companies and generic manufacturers navigating patent litigation after the U.S. Supreme Court's decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

The June 4 ruling (No. 24-889) held that induced patent infringement requires "affirmative, targeted conduct that actively encourages infringement." But the more consequential detail, according to Ballard Spahr's 2026 Life Sciences Report, is what that standard rules out: ordinary distribution of a generic drug, lawful statements describing it as equivalent to the brand-name product, and FDA-required or industry-standard communications are not, by themselves, enough to support an infringement claim.

That distinction matters because it directly addresses the kind of evidence brand companies have relied on in past skinny-label disputes. The case centered on generic icosapent ethyl, sold under the brand name Vascepa by Amarin Pharma. Under the Hatch-Waxman Act's Section viii "carve-out" provision, a generic manufacturer can omit a still-patented use from its label while marketing the drug for its remaining, unpatented uses. Hikma had fully carved out Amarin's patented indication for reducing cardiovascular risk in patients with elevated triglycerides — yet the Federal Circuit had still allowed Amarin's infringement claims to proceed, pointing to Hikma's press releases, AB-rating references and statements calling its product a "generic version" of Vascepa. The Supreme Court reversed, finding that record insufficient.

Ballard Spahr's analysis lays out what a viable infringement complaint now needs to look like: concrete statements or actions tied specifically to the patented, carved-out indication, such as sales scripts, physician-facing marketing materials, payer presentations or promotional content connecting the generic product to the protected use. General marketing language or routine regulatory filings won't clear that bar on their own.

For physicians, the shift is likely to register indirectly, through prescribing and pharmacy substitution rather than anything that changes in the exam room. A more predictable, less litigation-prone skinny-label pathway generally supports faster generic entry for the non-patented uses of a drug, which can affect formulary status, pharmacy substitution and out-of-pocket costs for patients using a medication for indications outside a brand's remaining patent protection.

The analysis is careful to note the ruling isn't a blanket safe harbor. Generic manufacturers still need to keep FDA labeling, investor communications and sales training consistent with an approved carve-out — marketing that strays into promoting the still-patented use could reopen the door to a claim. But Ballard Spahr's attorneys write that the decision meaningfully reduces the litigation risk that had made the skinny-label pathway unreliable in practice, even when a carve-out was properly executed.

On the brand side, the firm advises drugmakers to respond by tightening how they draft and prosecute method-of-use patents, and by reassessing use-code descriptions and Orange Book listings so patent claims map as closely as possible to the portions of a label a generic competitor can't avoid.

The guidance lands amid a broader wave of patent activity the same report tracks across the life sciences sector. An approaching "patent cliff" — tens of billions of dollars in brand-name drug revenue expected to lose exclusivity over the next several years — has already reshaped merger and acquisition activity as companies look to replace at-risk revenue. Generic and biosimilar competition remains one of the primary levers regulators and payers point to for controlling long-term drug costs, which is what makes a law firm's read on how far brand companies can push infringement claims against skinny-label competitors relevant well beyond the legal trade press.